Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204287844> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3204287844 endingPage "S581" @default.
- W3204287844 startingPage "S581" @default.
- W3204287844 abstract "Angiogenesis is associated with tumor progression, and antiangiogenic molecules have become a cornerstone in the treatment of advanced colorectal cancer (CRC). Regorafenib is a multi-kinase inhibitor targeting VEGFR1, 2, 3, TIE2, KIT, RET, RAF-1, BRAF, BRAFV600E, PDGFR, FGFR, and is an effective option in 20-25% of heavily pre-treated patients. Other therapies target the tumoral micro-environment, as metronomic chemotherapy (CT), with continuous low dose administration of a cytotoxic agent. This allows an anti-tumor effect, an anti-angiogenic activity, a stimulation of the immune system, and a better tolerance. A recent study performed in 66 metastatic CRC patients showed that aspirin and metronomic capecitabine administration was safe and induced promising clinical outcomes in a heavily pre-treated cohort (Giampieri et al, 2017). Following these clinico-biological observations, the REPROGRAM-01 study has been initiated. This is a French multi-center single-arm phase II study. Patients with metastatic CRC in progression after previous standard treatments, or who are not considered candidates for them, receive regorafenib with metronomic CT. Regorafenib is delivered according to the REDOS schedule (80 mg for week 1, 120 mg for week 2 and 160 mg for week 3 of the first cycle) and is administered 3 weeks out of 4, until progression. Metronomic CT is the association of capecitabine (625mg/m2 twice daily continuously for 6 months) with cyclophosphamide (50 mg daily for 6 months). Aspirin (75 mg once daily) is added until progression. The primary endpoint is overall response rate. Secondary endpoints are overall survival, progression-free survival, health related quality of life, toxicity, and the evaluation of exploratory biomarkers. A thorough monitoring of biological and radiological parameters will be undertaken to characterize the impact of this association on the reprogramming of immunological responses and on the stroma. Assuming a significance level of 5% and a power of 80%, a sample size of 49 patients is needed. The enrollment is ongoing,12 patients have already been recruited. 2020-002344-23. Centre Hospitalier Régional et Universitaire Jean Minjoz, Besançon, France." @default.
- W3204287844 created "2021-10-11" @default.
- W3204287844 creator A5000284560 @default.
- W3204287844 creator A5000366365 @default.
- W3204287844 creator A5014323516 @default.
- W3204287844 creator A5022288769 @default.
- W3204287844 creator A5037845833 @default.
- W3204287844 creator A5038095307 @default.
- W3204287844 creator A5039623582 @default.
- W3204287844 creator A5049066033 @default.
- W3204287844 creator A5051338463 @default.
- W3204287844 creator A5064460228 @default.
- W3204287844 creator A5067565814 @default.
- W3204287844 creator A5070426915 @default.
- W3204287844 creator A5070987839 @default.
- W3204287844 creator A5071590361 @default.
- W3204287844 creator A5075053811 @default.
- W3204287844 creator A5075690105 @default.
- W3204287844 creator A5080127868 @default.
- W3204287844 creator A5091838486 @default.
- W3204287844 date "2021-09-01" @default.
- W3204287844 modified "2023-10-18" @default.
- W3204287844 title "509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer" @default.
- W3204287844 doi "https://doi.org/10.1016/j.annonc.2021.08.1028" @default.
- W3204287844 hasPublicationYear "2021" @default.
- W3204287844 type Work @default.
- W3204287844 sameAs 3204287844 @default.
- W3204287844 citedByCount "0" @default.
- W3204287844 crossrefType "journal-article" @default.
- W3204287844 hasAuthorship W3204287844A5000284560 @default.
- W3204287844 hasAuthorship W3204287844A5000366365 @default.
- W3204287844 hasAuthorship W3204287844A5014323516 @default.
- W3204287844 hasAuthorship W3204287844A5022288769 @default.
- W3204287844 hasAuthorship W3204287844A5037845833 @default.
- W3204287844 hasAuthorship W3204287844A5038095307 @default.
- W3204287844 hasAuthorship W3204287844A5039623582 @default.
- W3204287844 hasAuthorship W3204287844A5049066033 @default.
- W3204287844 hasAuthorship W3204287844A5051338463 @default.
- W3204287844 hasAuthorship W3204287844A5064460228 @default.
- W3204287844 hasAuthorship W3204287844A5067565814 @default.
- W3204287844 hasAuthorship W3204287844A5070426915 @default.
- W3204287844 hasAuthorship W3204287844A5070987839 @default.
- W3204287844 hasAuthorship W3204287844A5071590361 @default.
- W3204287844 hasAuthorship W3204287844A5075053811 @default.
- W3204287844 hasAuthorship W3204287844A5075690105 @default.
- W3204287844 hasAuthorship W3204287844A5080127868 @default.
- W3204287844 hasAuthorship W3204287844A5091838486 @default.
- W3204287844 hasBestOaLocation W32042878441 @default.
- W3204287844 hasConcept C121608353 @default.
- W3204287844 hasConcept C126322002 @default.
- W3204287844 hasConcept C143998085 @default.
- W3204287844 hasConcept C2776248978 @default.
- W3204287844 hasConcept C2776694085 @default.
- W3204287844 hasConcept C2777802072 @default.
- W3204287844 hasConcept C2780394083 @default.
- W3204287844 hasConcept C502942594 @default.
- W3204287844 hasConcept C526805850 @default.
- W3204287844 hasConcept C71924100 @default.
- W3204287844 hasConceptScore W3204287844C121608353 @default.
- W3204287844 hasConceptScore W3204287844C126322002 @default.
- W3204287844 hasConceptScore W3204287844C143998085 @default.
- W3204287844 hasConceptScore W3204287844C2776248978 @default.
- W3204287844 hasConceptScore W3204287844C2776694085 @default.
- W3204287844 hasConceptScore W3204287844C2777802072 @default.
- W3204287844 hasConceptScore W3204287844C2780394083 @default.
- W3204287844 hasConceptScore W3204287844C502942594 @default.
- W3204287844 hasConceptScore W3204287844C526805850 @default.
- W3204287844 hasConceptScore W3204287844C71924100 @default.
- W3204287844 hasLocation W32042878441 @default.
- W3204287844 hasOpenAccess W3204287844 @default.
- W3204287844 hasPrimaryLocation W32042878441 @default.
- W3204287844 hasRelatedWork W1965063355 @default.
- W3204287844 hasRelatedWork W1971832196 @default.
- W3204287844 hasRelatedWork W2887131050 @default.
- W3204287844 hasRelatedWork W2907419770 @default.
- W3204287844 hasRelatedWork W2914832607 @default.
- W3204287844 hasRelatedWork W2952022705 @default.
- W3204287844 hasRelatedWork W3030758306 @default.
- W3204287844 hasRelatedWork W3030909497 @default.
- W3204287844 hasRelatedWork W3142077694 @default.
- W3204287844 hasRelatedWork W861557199 @default.
- W3204287844 hasVolume "32" @default.
- W3204287844 isParatext "false" @default.
- W3204287844 isRetracted "false" @default.
- W3204287844 magId "3204287844" @default.
- W3204287844 workType "article" @default.